EANS-News: DEWB Investment Holding NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Berlin, Germany, May 18, 2010 (euro adhoc) - NOXXON Pharma AG (NOXXON), a
company focused on the development of mirror image oligonucleotide therapeutics
called Spiegelmers®, announced today the appointment of Dr. Aram Mangasarian as
Chief Business Officer and Member of the Executive Committee. Dr. Mangasarian
will be responsible for corporate and business development activities for
NOXXON.

Dr. Mangasarian brings to NOXXON more than 10 years of business development and
strategic planning experience within the biotechnology and pharmaceutical
industry. He joins NOXXON from Novexel, a French venture-funded anti-infectives
company, which was recently acquired by AstraZeneca (NYSE:AZN), where he held
the position of Vice President of Business Development. Prior to Novexel, Dr.
Mangasarian served as Vice President of Business Development at ExonHit
Therapeutics (Alternext:ALEHT). As graduate of the University of California, San
Diego, Dr. Mangasarian earned his PhD in the Department of Biology by conducting
research on HIV. He also holds an MBA from INSEAD. In his career he has
successfully negotiated licensing transactions and strategic alliances with
major pharmaceutical companies.

Dr. Mangasarian will work side by side with Dr. Frank Morich, NOXXON´s Chief
Executive Officer, and Dr. Sven Klussmann, Chief Scientific Officer. "Dr.
Mangasarian brings to NOXXON an outstanding combination of business experience
and scientific understanding." said Dr. Morich. "I am confident that Dr.
Mangasarian is more than qualified to contribute to NOXXON´s further development
in the biopharmaceutical industry. We all look forward to working with him."

"The recent positive results from the Phase I clinical trials of NOX-E36 and
NOX-A12 make it a very exciting time to join NOXXON. I look forward to further
developing NOXXON´s corporate strategy and to rapidly advancing ongoing business
discussions." commented Dr. Aram Mangasarian newly-appointed Chief Business
Officer at NOXXON.

About NOXXON
Berlin-based NOXXON Pharma AG is a clinical stage biotechnology company focusing
on the development of Spiegelmers® for the treatment of various disease
indications. NOXXON is in possession of a broad patent estate and has access to
a readily scalable GMP production. In addition to its in-house programs, NOXXON
discovers and develops Spiegelmers® in collaboration with partners from the
pharmaceutical industry, including Eli Lilly and Hoffmann La-Roche. The business
strategy of NOXXON is to broaden this range of collaborations through
co-development and licensing agreements for the proprietary clinical and
pre-clinical products as well as technology-based multi-target partnerships.
Currently, the company has two compounds in clinical development. The declared
goal of NOXXON is to establish its oligonucleotide-based drug discovery platform
(Spiegelmers®) as the leading 'scaffold' technology to create new chemical
entities with superior properties. NOXXON´s investors are TVM Capital, Sofinnova
Partners, Edmond de Rothschild Investment Partners, Deutsche Effecten- und
Wechsel-Beteiligungsgesellschaft (DEWB), Seventure Partners, Dow Venture
Capital, Dieckell Group, FCP OP MEDICAL BioHealth- Trends, IBG
Risikokapitalfonds, VC Fonds Berlin, and others.
Webseite: http://www.noxxon.com

General contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: + 49-30-726247-100
FAX: + 49-30-726247-225
Email: [email protected]

Further inquiry note:
Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: [email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Leutragraben 1
D-07743 Jena
phone: +49 (0)3641 573 3600
FAX: +49 (0)3641 573 3610
mail: [email protected]
WWW: http://www.dewb-vc.com
sector: Financial & Business Services
ISIN: DE0008041005
indexes: CDAX, Classic All Share
stockmarkets: free trade: Berlin, Stuttgart, München, regulated dealing/general
standard: Frankfurt
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print